So much to say, so little space. FDA-led studies assess risk information on social media

Nicole DeFeudis

Editor

How should pharma companies use the limited character space in a promotional tweet? While including risk information in the body of a post made patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

So much to say, so little space. FDA-led studies assess risk information on social media

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Purdue, Sacklers reach new $7.4B opioid settlement after SCOTUS rejection

BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

As another Trump term gets underway, pharma advisors get comfortable with uncertainty

AbbVie partners with Neomorph in latest molecular glue deal

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

So much to say, so lit­tle space. FDA-led stud­ies as­sess risk in­for­ma­tion on so­cial me­dia

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

So much to say, so little space. FDA-led studies assess risk information on social media